BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fumoto S, Yamamoto T, Okami K, Maemura Y, Terada C, Yamayoshi A, Nishida K. Understanding In Vivo Fate of Nucleic Acid and Gene Medicines for the Rational Design of Drugs. Pharmaceutics 2021;13:159. [PMID: 33530309 DOI: 10.3390/pharmaceutics13020159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Hu D, Fumoto S, Yoshikawa N, Peng J, Miyamoto H, Tanaka M, Nishida K. Diffusion coefficient of cationic liposomes during lipoplex formation determines transfection efficiency in HepG2 cells. Int J Pharm 2023;:122881. [PMID: 36963641 DOI: 10.1016/j.ijpharm.2023.122881] [Reference Citation Analysis]
2 Kates PA, Cook JN, Ghan R, Nguyen HJ, Sitasuwan P, Lee LA. Incorporation of automated buffer exchange empowers high-throughput protein and plasmid purification for downstream uses. SLAS Technol 2023:S2472-6303(23)00005-5. [PMID: 36736961 DOI: 10.1016/j.slast.2023.01.005] [Reference Citation Analysis]
3 D'Souza A, Nozohouri S, Bleier BS, Amiji MM. CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood-Brain Barrier and Towards Specific Cellular Targeting. Pharm Res 2023;40:77-105. [PMID: 36380168 DOI: 10.1007/s11095-022-03433-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zhang L, Liang Y, Liang G, Tian Z, Zhang Y, Liu Z, Ji X. The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates. Front Pharmacol 2022;13:1090237. [PMID: 36588695 DOI: 10.3389/fphar.2022.1090237] [Reference Citation Analysis]
5 Morales-Becerril A, Aranda-Lara L, Isaac-Olivé K, Ocampo-García BE, Morales-Ávila E. Nanocarriers for delivery of siRNA as gene silencing mediator. EXCLI J 2022;21:1028-52. [PMID: 36110562 DOI: 10.17179/excli2022-4975] [Reference Citation Analysis]
6 Pengnam S, Plianwong S, Yingyongnarongkul BE, Patrojanasophon P, Opanasopit P. Delivery of small interfering RNAs by nanovesicles for cancer therapy. Drug Metab Pharmacokinet 2021;42:100425. [PMID: 34954489 DOI: 10.1016/j.dmpk.2021.100425] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Oyama S, Yamamoto T, Yamayoshi A. Recent Advances in the Delivery Carriers and Chemical Conjugation Strategies for Nucleic Acid Drugs. Cancers (Basel) 2021;13:3881. [PMID: 34359781 DOI: 10.3390/cancers13153881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Graceffa V. Physical and mechanical cues affecting biomaterial-mediated plasmid DNA delivery: insights into non-viral delivery systems. J Genet Eng Biotechnol 2021;19:90. [PMID: 34142237 DOI: 10.1186/s43141-021-00194-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]